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Executive (dys)function after traumatic brain injury: special
considerations for behavioral pharmacology
Jenny E. Ozgaa, Jessica M. Povroznikb, Elizabeth B. Engler-Chiurazzib
and Cole Vonder Haara
Executive function is an umbrella term that includes
cognitive processes such as decision-making, impulse
control, attention, behavioral flexibility, and working
memory. Each of these processes depends largely upon
monoaminergic (dopaminergic, serotonergic, and
noradrenergic) neurotransmission in the frontal cortex,
striatum, and hippocampus, among other brain areas.
Traumatic brain injury (TBI) induces disruptions in
monoaminergic signaling along several steps in the
neurotransmission process – synthesis, distribution, and
breakdown – and in turn, produces long-lasting deficits in
several executive function domains. Understanding how TBI
alters monoamingeric neurotransmission and executive
function will advance basic knowledge of the underlying
principles that govern executive function and potentially
further treatment of cognitive deficits following such injury.
In this review, we examine the influence of TBI on the
following measures of executive function – impulsivity,
behavioral flexibility, and working memory. We also describe

Introduction
Traumatic brain injury (TBI) occurs when an external force
(e.g. mechanical deformation, rapid deceleration, blast
wave) is applied to the brain and affects more than 200 per
100 000 people each year globally (Bryan-Hancock and
Harrison, 2010). While many people recover with minimal
complications, a significant portion goes on to develop
chronic behavioral and cognitive deficits, resulting in an
estimated 1–2% of people with TBI-related disabilities
(Thurman et al., 1999; Zgaljardic et al., 2015), and accounting
for a staggering $76.5 billion USD economic burden as of
2010, with 10-year costs averaging $270 000 per patient
(Corso et al., 2006; Coronado et al., 2012; Ponsford et al.,
2013). Brain injury is considered to be a major risk factor in
the development of neurodegenerative disorders, including
Parkinson’s and Alzheimer’s diseases (Semchuk et al., 1993;
Plassman et al., 2000), and is associated with increased rates
of depression, anxiety, attention-deficit disorders, suicidality,
and substance abuse following such central nervous system
damage (Moor et al., 2006; Vaishnavi et al., 2009; Rao et al.,
2010; Konrad et al., 2011; Reeves and Panguluri, 2011;
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monoaminergic-systems changes following TBI. Given that
TBI patients experience alterations in monoaminergic
signaling following injury, they may represent a unique
population with regard to pharmacotherapy. We conclude
this review by discussing some considerations for
pharmacotherapy in the field of TBI. Behavioural
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Zgaljardic et al., 2015). Notably, these disorders impair a
wide variety of behaviors commonly considered under the
umbrella of ‘executive function,’ including memory, behavioral flexibility, impulsivity, and decision-making (Alves
et al., 2014; Bredemeier and Miller, 2015; Day et al., 2015;
Sharp et al., 2015; Kingdon et al., 2016).
Given the considerable difficulty of determining the causes
of executive function deficits in clinical TBI patients,
several injury models have been developed for inducing
experimental TBIs in nonhuman animals, that map on to
clinical injuries and severities (Morganti-Kossmann et al.,
2010). These injury types may be induced using various
methods (e.g. controlled-cortical impact, fluid percussion,
weight drop, blast) and at a spectrum of severities, each
with unique pathological characteristics. Focal injuries result
largely in localized contusion and cell death while being
highly reproducible in the animal laboratory. In contrast,
concussive and blast injuries generate a diffuse pattern of
injury with axonal shearing that are less reproducible than
focal injuries. In animal models, severity of injury is directly
related to the amount of force applied to the animal’s brain
and strongly tied to neurological outcome (Xiong et al., 2013),
while clinical measurements rely on neurological outcomes
such as the Glasgow Coma Scale to assess severity (Teasdale
and Jennett, 1974). Regardless of primary injury type, cascades of secondary damage are initiated, which may include
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neurochemical and ionic disequilibrium in neurons, depletion of cellular energy reserves, mitochondrial dysfunction,
lipid peroxidation and DNA damage, upregulated neuroinflammation, and compromised glial and endothelial support
networks, that coalesce to contribute to enduring dysfunction
after TBI (Prins et al., 2013).
While various animal models have been used for several
decades to study the pathology of brain injury, only
recently has more attention been given to behavioral
assessment of higher-order function. For many decades,
the primary assessment of cognitive function after such
trauma has been the Morris water maze (MWM), a task
designed to measure hippocampal function (Morris,
1984). While this has proven to be very effective in
rapidly assessing the effects of TBI on spatial learning
and reference memory in animals, it is difficult to ascertain changes associated with a variety of other executive
functions using this task. More recent studies have begun
to make use of a wider variety of paradigms to measure
cognition, including several methods based on standard
operant techniques, which are the focus of this review.
To date, no pharmacological agents have been approved
for the treatment of TBI, either in the acute or the chronic
period. In particular, it is unclear whether patients with
injury-induced psychiatric conditions represent a special
population with regard to pharmacotherapies, and the
degree to which commonly prescribed drugs are appropriate for patients with a TBI. Thus, the purpose of the
present review is to (i) survey the literature on executive
function assessments following human and animal brain
injury; (ii) describe monoaminergic-systems changes following TBI that may influence how deficits in executive
function respond to pharmacological intervention; and (iii)
discuss considerations for behavioral pharmacology and
pharmacotherapies in TBI.

Executive function following traumatic brain
injury
Impulsivity

Impulsivity is a multifaceted concept describing actions
with the potential to provide short-term gain at a cost to
long-term benefits. The construct can be subdivided into
motor impulsivity (i.e. failure to inhibit responding), choice
impulsivity (i.e. inability to wait for delayed reinforcers or
issues with delayed gratification), and sometimes risktaking (i.e. choosing larger outcomes that are uncertain
over smaller outcomes that are certain). Human studies
suggest that deficits involving impulsivity following TBI
are particularly problematic because of their wide impact
on daily function (Rochat et al., 2010; James et al., 2014) and
animal models with high translational validity have been
developed within each realm of impulsive behavior.
Motor impulsivity

Motor impulsivity, also known as response disinhibition,
refers broadly to acting without thinking. Response

inhibition can be further divided into ‘stopping’ and
‘waiting’ impulsivity (Schachar et al., 2007; Robinson
et al., 2009), in which ‘stopping’ impulsivity refers to the
inability to stop an action that has already been initiated,
while ‘waiting’ impulsivity refers to the inability to
inhibit responding for an extended duration (i.e. premature responding). One of the clinical manifestations of
increased motor impulsivity is impulsive aggression,
which is also correlated with criminal behavior after TBI
(Alderman, 2003; Dyer et al., 2006; Wood and Thomas,
2013). Impulsive aggression is operationalized as a quick,
impulsive, aggressive response following minimal provocation (Barratt et al., 1997), and in its verbal form is
relatively common during acute recovery post-TBI
(35–38%; according to Dyer et al., 2006), although physical aggression may also be present (Dyer et al., 2006;
Rao et al., 2009). Thus, deficits in motor impulsivity postTBI have the potential to drastically impact quality of life
for individuals with TBI, and their close relations.
Clinical evidence: There are several procedures for assessing motor impulsivity in humans, including go/no-go
tasks (Donders, 1969), stop-signal tasks (SST; Logan,
1994), and continuous performance tasks (CPT; Rosvold
et al., 1956). For humans, reinforcers are presented typically in the form of ‘points’ such as those delivered in
a game.
During go/no-go tasks, response inhibition is evaluated
by pairing a cue (e.g. tone, symbol) with each type of trial
– ‘go’ and ‘no-go’ trials – to aid in discrimination between
the two alternatives. In general, if responding is inhibited
during the ‘no-go’ signal, a reinforcer is delivered, while
responses are punished with a timeout. The opposite
occurs during ‘go’ signals, with reinforcement of
responses and punishment of nonresponding. The SST is
a more complex version of go/no-go, where response
inhibition is tested further as participants must inhibit an
action that is already in progress. A rapid response
sequence is trained on two different options to receive a
reinforcer. At random intervals within the session, a stimulus is presented (typically a tone), which signals that
response inhibition will be reinforced. Stopping difficulty
is increased by parametrically manipulating the delay to
presentation of the ‘stop’ trial signal, and the signal is not
given until a motor action is already in progress.
Specifically, the task is designed to measure the longest
delay under which an already-initiated action can be
inhibited. Those with poorer inhibitory control will
require shorter delays and have increased stop-signal
reaction times (Logan, 1994). Nativ et al. (1994) and
Rochat et al. (2013) used the SST to assess stopping
impulsivity of patients following moderate-to-severe
TBIs as compared with healthy controls matched for
handedness or age. Stimuli were different colored lights
and participants were instructed to respond as quickly as
possible in the presence of one color and to stop
responding in the presence of the alternative color.
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During this procedure, TBI patients had significantly
longer latencies to inhibit responding relative to controls,
which is indicative of poorer response inhibition and
resistance to performance interference following injury.
CPTs are a popular tool for assessing sustained attention
and waiting impulsivity in various clinical populations
(Riccio et al., 2002). Such tasks require subjects to
respond when target stimuli are present (i.e. a specific
tone or light) and to inhibit responding when alternative,
distractor stimuli are present (Rosvold et al., 1956).
Duncan et al. (2005) and Chen et al. (2012) used visual
versions of the CPT to assess sustained attention and
motor impulsivity at 2 years and 1 month postmild concussive TBI, respectively, as compared with agematched, sex-matched, and education-matched controls.
Together, results from these studies indicate that TBI
patients have omission errors, comission errors, and
reaction times that are comparable to non-TBI participants, and that regardless of whether tested during acute
or chronic recovery, mild concussive TBI does not affect
performance on visual CPTs.
Preclinical evidence: Given the significance of motor
impulsivity problems in the clinical population, analogs
of the tasks described above have been designed to
assess motor impulsivity in preclinical animal models.
Many of the tasks map onto the human assessments quite
directly; however, reinforcers are typically delivered in
the form of food.
Similar to the clinical evidence discussed above, preclinical evidence using rats and mice suggests that mild
concussive experimental TBI produces deficits in stopping impulsivity in the go/no-go task, indicated by
increased latencies to inhibit responding when no-go
stimuli are presented (Hehar et al., 2015; Mychasiuk et al.,
2015). In addition to a significant main effect of TBI on
response inhibition, both of these studies also found that
deficits for male rats were significantly more pronounced
than those for female rats, suggesting that sex may play a
prominent role in how TBI affects response inhibition.
A similar deficit in latency to stop responding has been
shown when utilizing the SST in rats. In particular, following severe focal TBI to the bilateral medial frontal
cortex, response inhibition was impaired in rats when
assessed using a SST, indicated by increased stop-signal
reaction times and these deficits were exacerbated in rats
that underwent voluntary exercise during acute recovery
(Crane et al., 2012).
In contrast to the stop-signal and go/no-go tasks, differential reinforcement of low-rate responding (DRL)
schedules of reinforcement (Ferster and Skinner, 1957)
are free-operant arrangements and do not have designated ‘stop’ trials. Such reinforcement schedules are
designed to evaluate waiting impulsivity and include a
temporal duration in which lack of responding is reinforced. Specifically, if the time between two consecutive

responses is greater than some duration (set by the
experimenter), reinforcement occurs. If responding
occurs before the duration elapses, the timer is reset. For
example, on a DRL 20 s schedule, subjects must space
two consecutive responses by at least 20 s to receive
reinforcement. Severe focal injuries to the bilateral
frontal cortex in rats impaired performance on a DRL 20 s
schedule and deficits persisted until 11 months postinjury (Lindner et al., 1998), with TBI animals showing
an ~ 15% reduction in efficiency.
Another behavioral task developed for studying motor
impulsivity of nonhuman animals is the five-choice serial
reaction time task (5CSRTT), which is considered an
analog of human CPTs (Carli et al., 1983). During this
procedure, subjects must wait a period of time until the
brief illumination of one response option (commonly 0.5 s
duration), after which a response to that alternative is
reinforced. Because of the brief presentation of the stimulus, combined with punishment for incorrect or
omitted responses, the task sets up a prepotent motor
response, which is required to be inhibited for some
duration (commonly 5 s, although longer and variable
versions exist). Following reinforcer delivery, the next
trial may be initiated immediately. Failure to inhibit
leads to a timeout. Because each session is limited in
duration, excessive premature responding leads to delays
in reinforcement or even reduced total reinforcement. In
one study utilizing the 5CSRTT in rats, mild, moderate,
and severe focal TBI to the bilateral frontal cortex
resulted in a significant increase in premature responding, and deficits persisted for 14 weeks postinjury
(Vonder Haar et al., 2016).
Summary: While there are relatively few clinical and
preclinical studies on response inhibition following TBIs,
the existing evidence suggests that motor impulsivity
(both, stopping and waiting impulsivity) increases following even mild injuries. The use of a variety of procedures for assessing motor impulsivity, as well as injury
models, suggests that this is a robust phenomenon in the
preclinical literature. Further work is needed to dissociate the mechanisms by which TBI reduces response
inhibition in an effort to develop treatment strategies
specific to TBI-induced motor impulsivity.
Choice impulsivity

Choice impulsivity is a term that captures decisions that
result in immediate gains at the cost of long-term benefits. Commonly, this is referred to as ‘discounting’ the
value of future reinforcers/rewards, which is thought to
be because of the cost associated with waiting. One of the
most common ways for choice impulsivity to be measured is through tasks that manipulate delays and reinforcer magnitudes parametrically to determine individual
levels of temporal discounting, and impulsive choice is
operationalized as preference for smaller, immediate
reinforcers over larger, delayed reinforcers. Large-scale
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increases in choice impulsivity may result in overall poor
decision-making, which can cause financial difficulties,
physical health problems, and overall adverse life outcomes (Hamilton and Potenza, 2012; Boyle et al., 2013).
Clinical evidence: Impulsive choice is assessed primarily
using various delay discounting procedures. In general,
such procedures involve discrete-trials choices between a
smaller, more immediate reinforcer and a larger, delayed
reinforcer. For humans, reinforcers are hypothetical
monetary rewards in most cases. Although the basic
premise of delay discounting procedures is the same,
several variations exist, which differ in the way that
delays and/or reinforcer amounts are presented to subjects (Vanderveldt et al., 2016). For example, during the
‘adjusting-amount procedure’ (Du et al., 2002), the
magnitude of the smaller reinforcer is titrated during each
trial until a point of indifference is calculated, which is
defined as the magnitude at which the subject chooses
each magnitude/delay alternative with equal frequency.
In general, greater choice for the smaller, more immediate reinforcer is considered impulsive and results in
indifference points at smaller magnitudes.
Evidence from clinical TBI studies suggests that patients
display increased impulsive choice following TBI,
reporting that TBI patients choose smaller, immediate
reinforcers over larger, delayed reinforcers more than
healthy controls matched for age, sex, and educational
status (Dixon et al., 2005; McHugh and Wood, 2008;
Sellitto et al., 2010; Wood and McHugh, 2013). Such
deficits in choice impulsivity have been reported
following assessment on adjusting-amount procedures
using various hypothetical monetary amounts as well as
following mild, moderate, and severe concussive TBI to
the frontal cortex (Dixon et al., 2005; McHugh and Wood,
2008; Sellitto et al., 2010; Wood and McHugh, 2013).
Indeed, it seems as though deficits in choice impulsivity
may be frontally mediated given that patients with TBI
outside of the frontal lobe show performance similar to
that of healthy controls (Sellitto et al., 2010). However,
given the cross-sectional nature of clinical data in TBI
patients, a temporal pathway between occurrence of TBI
and choice impulsivity cannot be discerned.
Preclinical evidence: Despite the high translational validity
of delay discounting procedures for assessing choice
impulsivity, only one study has used it in the field of
experimental TBI, using the Evenden and Ryan (1996)
procedure. During this procedure, delays to the larger
reinforcer are systematically increased across blocks of
trials within each session while reinforcer magnitudes are
held constant. In general, choices are between one food
pellet delivered immediately and three food pellets
delivered after a delay. During the first block of trials, the
delay to both reinforcer options is 0 s, and the delay to the
larger reinforcer increases systematically across blocks
within sessions. Choice for the smaller, immediate

reinforcer is considered impulsive in conditions where
reinforcement can be maximized by maintaining exclusive choice for the larger, delayed reinforcer. Following
severe or mild focal TBI to the bilateral frontal cortex in
rats, impulsive choice increased, indicated by significantly more choice for the smaller, immediate reinforcer for TBI rats relative to shams (Vonder Haar et al.,
2017). Not surprisingly, deficits in choice impulsivity
were initially quite pronounced following severe TBI,
but actually recovered to sham levels. Surprisingly, while
mild TBI animals had relatively small increases in
impulsivity relative to shams, their deficits persisted for
the 8 weeks of testing. These results suggest that pure
tissue damage may not be a primary mechanism driving
impulsivity after TBI.
Summary: Impulsivity is a major issue for individuals
living with TBI. Notably, high levels of impulsivity could
also be a contributing risk factor to TBI in clinical
populations. However, at least in one study, choice
impulsivity was increased following experimental TBI,
lending support for a directional relationship between
clinical TBI and enhanced impulsive decision-making.
Despite this, preclinical data suggest that the persistence
of such deficits may be dependent upon the severity of
injury. Given that only one study has examined effects of
experimental TBI on choice impulsivity, further research
is needed to expand upon these findings using alternative delay discounting procedures and injury models.
Risk-taking

Risk-taking behaviors may be somewhat controversial to
include with impulsivity, as impulsivity is defined commonly to include actions/choices that will have long-term
detrimental effects. By contrast, risky decisions only
probably lead to long-term problems. However, they are
part of a cluster of symptoms identified in TBI patients,
have considerable overlap with impulsive behaviors, and
can lead to similar negative outcomes.
Clinical evidence

Numerous procedures exist for assaying risk-taking
behaviors in humans, including probability-discounting
tasks, various gambling tasks, the Balloon-Analog Risk
Task (BART), and others (Bechara et al., 1994; Rogers
et al., 1999; Lejuez et al., 2002). The most common
assessment for use with clinical populations is the Iowa
Gambling Task (IGT; Bechara et al., 1994). During the
IGT, 100 discrete-trials choices are presented between
four decks of cards, two of which are relatively ‘safe’ and
two of which are ‘risky’. The two ‘safe’ options are set up
to return the highest overall rate of reinforcement ($50
with frequent penalties ranging from $25 to $75, or $50
with infrequent penalties of $250), while the ‘risky’
options give large amounts, but low overall rates of
reinforcement ($100 with frequent penalties ranging from
$100 to $350, or $100 with infrequent penalties of $1250).
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MacPherson et al. (2009) and Cotrena et al. (2014) found
no differences in choice on the IGT between frontal TBI
patients and healthy controls matched for age and education status during the first 60 trials of the task (both
groups were largely indifferent between alternatives).
However, between trials 61 and 100, TBI patients
remained indifferent between options while controls
chose the two ‘safe’ options significantly more, suggesting that control participants may have been more sensitive to the contingencies associated with each alternative.
Xiao et al. (2013) observed a similar pattern of results with
frontal TBI patients, although deficits in risky decisionmaking were observed as early as trial 21 out of 100.
An alternative assessment for risk-taking behavior is the
Cambridge Gambling Task (CGT; Rogers et al., 1999),
which has the major advantage of presenting known
probabilities, and thus potentially achieving a more pure
measurement of risk preference. During this task, participants are presented with 10 boxes, some of which are
red and some blue, representing the probability for that
trial. There is a token hidden in one box and participants
must wager an amount on the box color in which they
believe the token is located. Participants ‘win’ the
wagered amount if they were correct or ‘lose’ if it is in the
other color box. The primary risk-taking outcome measure is ‘risk adjustment’ and is calculated as the percentage of points risked across more-certain to less-certain
probabilities. In addition, the latency between trial presentation and when participants place a bet is measured,
and reduced deliberation times are reflective of
enhanced motor impulsivity. When matched for age and
education status, TBI patients had higher risk adjustment on the CGT at 4 and 6 months postinjury (Salmond
et al., 2005; Newcombe et al., 2011). Brain injury patients
also showed reduced deliberation times, lending additional support for impaired response inhibition following
frontal TBI.
An alternative means for assessing risk tolerance is the
BART (Lejuez et al., 2002), in which discrete trials are
presented that begin with an un-inflated balloon on a
computer screen. Participants click a button to inflate the
balloon and gain two points per click. If the balloon is
over-inflated, it may burst and participants lose all points
acquired during the trial. The burst point varies unpredictably across trials such that participants cannot
develop a rule for how many times to click before the
balloon bursting. At any point during the trial, they may
click an alternative button to ‘cash out’ their acquired
points and move on to the next trial. During this procedure, a balance is needed between tolerating some risk,
but not too much, to maximize returns. The primary
dependent measure is risk tolerance, which is calculated
as the average number of clicks to inflate the balloon per
trial, excluding trials in which the balloon burst: more
clicks are indicative of greater risk tolerance and greater
risk-taking behavior. In the single study utilizing the

BART with TBI patients, adolescents at least 12 months
postinjury were assessed and compared with healthy
control participants matched for handedness, age, sex,
race/ethnicity, and maternal education status (Chiu et al.,
2012). During this task, no differences in risk tolerance
were observed between TBI and controls. The differences in findings between the BART and IGT/CGT are
interesting, and may be because of differences in clinical
samples (adolescent vs. adult), but also suggest that different risk-taking assessments may tap into alternative
forms of risk-based decision-making.
Preclinical evidence

Risk-taking behavior has been largely unstudied in animal models of TBI. Recently, our laboratory has performed one such study using a rodent analog of the IGT,
referred to as the rodent gambling task (RGT; Zeeb et al.,
2009). The primary difference between the IGT and
RGT is that the rodent version has a distinct, mostoptimal option, while on the IGT, the two ‘risky’ choices
and the two ‘safe’ choices are equivalent to one another.
As in the IGT, rats make choices among four options, two
‘safe’ and two ‘risky’. Each choice is associated with a
different number of sucrose pellets for ‘wins’ (1–4), and
different penalties for ‘losses’ (5–40 s timeout), with the
two-pellet option conferring the highest overall rate of
reinforcement, followed by the one-pellet option
(Winstanley and Clark, 2016). Following severe focal
TBI to the bilateral frontal cortex of rats, there was a
significant shift in choice away from the most-optimal
option (Shaver TK, Ozga JE, Zhu B, Anderson KG,
Martens KM, Vonder Haar C, unpublished data).
Notably, this shift in choice preference reflected an
increased preference for both the safer, slightly suboptimal one-pellet option, as well as the riskier threepellet and four-pellet options, highlighting a complex
decision-making phenotype. These deficits persisted for
12 weeks postinjury, and occurred even if rats were
extensively pretrained on the task before injury.
Summary

The clinical literature emphasizes risk-taking as a major
concern for patients with TBI. However, phenotypes are
complex, as illustrated by differences in the BART and
other gambling tasks. Further, preclinical evidence is
quite limited, and identifies a more generalized deficit
that may not be selective to risk-taking, but instead, may
be more reflective of a generalized change in reinforcement/punishment sensitivity. Further research will be
needed to identify which aspects of cognitive-behavioral
therapies may be directed toward these patients.
Behavioral flexibility

Behavioral flexibility refers to the ability to adapt to
changing reinforcement contingencies and is often contrasted with perseveration. It is typically assessed with
discrimination-reversal procedures of varying complexity,
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several of which have been used in the fields of clinical
and experimental TBI (Berg, 1948; Daum et al., 1989;
Sherer et al., 2003; Hashimoto and Toshima, 2005; Myers
et al., 2006; Martens et al., 2012; Martens et al., 2013;
Bondi et al., 2014; Vonder Haar et al., 2014a; Chou et al.,
2016).
Clinical evidence

In simple discrimination-reversal learning, subjects are
trained to discriminate between two response alternatives
that are distinguished by set stimuli (e.g. lights, shapes)
and that discrimination is subsequently reversed. During
the task, discrete trials are presented in which responding
associated with the ‘correct’ stimulus is reinforced, while
responses to other alternatives are on extinction. Once
discrimination occurs reliably, the contingencies are
reversed and the number of trials required to shift to a
predefined mastery criterion is taken as a measure of
behavioral flexibility, in which more trials are indicative
of less flexibility. During simple discrimination-reversal
assessments using lights, tones, or shapes as discriminative stimuli, TBI patients require more trials to
reach mastery criteria relative to non-TBI patients matched for age and handedness (Daum et al., 1989;
Hashimoto and Toshima, 2005; Myers et al., 2006) and
never meet such criteria in some cases (Daum et al., 1989;
Hashimoto and Toshima, 2005).
Another flexibility measurement, the Wisconsin Card
Sorting Task (Berg, 1948), is commonly used in neuropsychiatric testing. In the task, participants are given
several cards in a deck and asked to sort them, but are not
told how the cards should be sorted. There are multiple
classification systems (e.g. color, shape, number,) and
each time the participant sorts a card, the experimenter
tells them whether the classification is correct or not.
However, after 10 cards are sorted correctly, the classification system changes and the number of trials required
for participants to adapt to the new classification is taken
as a measure of behavioral flexibility. On this task,
patients with moderate-to-severe TBI are impaired and
require more trials to meet mastery criterion (Sherer et al.,
2003). However, this task is not sufficient in and of itself
to delineate those with the worst TBI-related deficits
(Greve et al., 2002, 2009).
Preclinical evidence

Animal models largely mirror the clinical tasks with
regard to assessing flexibility, with stimuli (e.g. lights,
odors, tones) and response options (e.g. lever press, nose
poke) that are relevant for the animal. Severe focal TBI
to the frontal cortex impairs behavioral flexibility using
simple discrimination-reversal tests in rats and mice.
Specifically, TBI animals show a range of deficits from
small (additional trials or sessions to criterion) to major
(never achieving criterion) during postacute and early
chronic recovery periods (2–5 weeks postinjury; Martens

et al., 2012; Bondi et al., 2014; Vonder Haar et al., 2014a,
2014b; Chou et al., 2016). In addition to acute impairments, Chou et al. (2016) suggest that deficits persist for
5.5 months postinjury.
Additional complexity can be added to discriminationreversal tasks in nonhuman animals by utilizing complex
multimodal discriminative stimuli (e.g. odor + texture,
light + location), and shifting the discrimination only
along one dimension of discriminability. This procedure,
known as attentional set-shifting (Birrell and Brown,
2000), is roughly analogous to the Wisconsin Card Sorting
Task used with humans. This results in a subtler shift in
reinforcement contingencies (50% reinforced rather than
extinction), which can make for a more difficult task.
This form of learning is also impaired following unilateral
parietal focal injury in rats, although only at higher injury
severities (Bondi et al., 2014), but unaffected by unilateral
frontal focal injury (Chou et al., 2016).
Summary

Impairments in flexibility affect an individual’s ability to
appropriately change in response to their environment in
a fundamental way, and may contribute to a poorer
quality of life for individuals with TBI who report these
symptoms. This phenomenon has been replicated in the
preclinical literature, but only after relatively severe
injuries, potentially limiting its applicability to the clinical condition. However, these data may serve as a
starting point for the evaluation of pharmacotherapies,
and could be extended to more complex discriminationreversal procedures and more mild injury models.
Working memory

Working memory (WM) refers to the ability to remember
a given stimulus over a relatively short time frame
(commonly seconds to minutes). The assessment of WM
typically involves presenting a stimulus, removing it for a
given delay, and then testing for recall.
Clinical evidence

Numerous procedures exist for assessing WM in humans
using verbal, visual, and spatial modalities (Dunning
et al., 2016). Two common procedures that have been
used in the field of clinical TBI are the digit-span and nback tasks (Asloun et al., 2008; Levin et al., 2002; Chen
et al., 2012). The digit-span task measures verbal WM
and presents a sequence of numbers as the stimulus,
which subjects are then asked to reproduce after a brief
delay. Sequence length is gradually increased with each
correct response. The primary dependent measure in this
task is the number of digits correctly remembered in
sequence, with fewer digits indicating impaired WM.
Digit span is commonly included as part of the Weschler
Adult Intelligence Test battery, and so has been fairly
extensively tested. While it is relatively common to find
some level of impairment post-TBI (Scherwath et al.,
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2011; Woods et al., 2011), there are studies that report no
effect after milder TBI (Demery et al., 2010; Chen et al.,
2012). In addition, some researchers have noted that this
task may be confounded by the motivation of the individual, potentially exacerbating measurements in TBI
populations (Clark et al., 2014; West et al., 2011).
Similar to the digit-span task, the n-back task presents a
sequence of stimuli (commonly numbers or letters), one
at a time. During each stimulus presentation, the participant is instructed to identify whether the current stimulus is the same as the one presented n trials
(commonly 2 or 3) before the current stimulus. Thus, if
n = 3, the participant must identify when the current
stimulus matches the one presented three trials before
the current stimulus, typically with a mouse click or
button press. Task difficulty increases as n increases and
thus, the primary dependent measure is typically the
proportion of correct responses at 2-back or 3-back, with
smaller proportions indicating impaired WM. Levin et al.
(2002) assessed WM of adolescents five years postmild or
postsevere TBI compared with healthy controls, matched
for age and parental education status, using 1-back,
2-back, and 3-back tasks. Adolescent patients with brain
injuries demonstrated reduced WM performance on all
three task levels. Similarly, adult patients with severe or
mild TBI showed reduced WM performance on 1-back,
2-back, and 3-back tasks compared with matched control
participants (Asloun et al., 2008; Chen et al., 2012).
Preclinical evidence

Despite the potential impact on daily function in clinical
populations, memory impairments following experimental TBI have primarily been studied using the
MWM, and largely focused on reference memory as
opposed to WM. However, alternative measures for
assessing WM deficits include variants of the MWM as
well as delayed match-to-sample (DMTS) tasks. Here,
we limit our discussion to these, given that they are
highly dependent upon executive function relative to the
traditional reference MWM.
Morris water maze variants

The traditional form of the MWM is ubiquitous in the
field of experimental TBI. In this task, animals are placed
in a tank of water, and may escape by locating a submerged platform. Animals gradually reduce their latency
to escape using visual cues located around the room,
typically considered a measure of reference memory that
is highly hippocampal-dependent (Morris, 1984). Several
variations of the MWM have been implemented aimed at
assessing WM. These variations include a moving platform wherein the animals’ ability to track changing
locations of the platform is assessed (Hamm et al., 1996;
Hoane et al., 2003). During testing, the platform is submerged in a new quadrant of the MWM tank. After the
platform is placed in its new location, animals are placed

into the tank and given a brief period of time to locate the
platform. If the platform is not located by the animal after
the time interval elapses, the experimenter guides the
animal to the platform. Following the first trial, considered an ‘information’ trial, additional trials are conducted with several minutes separating the start of each
trial, and latencies to find the platform are taken as a
measure of WM function. Because of the length of this
delay, these procedures are considered different from
delayed match-to-sample parameters described below,
although there is considerable overlap. Longer latencies
on this procedure have been indicative of WM deficits
following moderate bilateral parietal (Hamm et al., 1996),
severe frontal (Hoane et al., 2003, 2004, 2005; Kokiko
et al., 2006) and severe unilateral parietal TBIs (Quigley
et al., 2009; Swan et al., 2011) during acute recovery.
Evaluation of chronic deficits has been limited, but
unpublished data suggest that WM impairments do not
resolve after focal, frontal TBI (Fig. 1).
Delayed match-to-sample

In general, DMTS procedures include a sample stimulus,
followed by two comparison stimuli, and choice for one of
the two comparison stimuli is recorded. Choice for the
comparison stimulus that matches the sample stimulus is
reinforced, while choice for the novel comparison stimulus results in extinction or timeout. Following accurate discrimination between the two comparison stimuli
and correct ‘matching’ to some criterion, a delay is
introduced such that the animal must remember which
sample stimulus was presented for a period of time
before the comparison stimuli are presented. A ‘nonmatch’ version of this procedure follows an opposite rule
in which animals must identify the stimulus that is novel
after the delay.
Various DMTS procedures have been used in the field of
experimental TBI where stimuli are associated with
spatial location. In one study that used an operant
chamber for WM assessment in rats (Lindner et al., 1998),
one lever was extended into the chamber and a response
on that lever resulted in lever retraction (sample stimulus). Following an intertrial interval, which varied from 0
to 50 s, both levers were extended into the chamber (i.e.
comparison stimuli) and animals were trained to respond
on the lever that did not match the sample stimulus (nonmatch-to-sample). Following severe focal injuries to the
lateral sensorimotor cortex, rats demonstrated a transient
impairment, while those that received severe bilateral
frontal cortex injuries, had deficits that lasted up to
11 weeks postinjury.
Although operant techniques represent a common procedure for testing WM, various maze assessments are
more prevalent in experimental TBI (e.g. T-mazes and
eight-arm radial mazes). In general, T-mazes have
included a platform that allows animals to escape from a
tub of water (Whiting and Hamm, 2006; Hoskison et al.,
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Fig. 1

Long-term, selective deficits in working memory after traumatic brain injury (TBI) (Martens KM, Vonder Haar C, Swan AA, Emery MA, Clayton ER,
Peterson TC, Hoane MR, unpublished data). Rats (3 months of age) received a bilateral frontal, focal TBI and were tested up to 18 months postinjury.
(a) TBI caused deficits in the reference version of the Morris water maze (P = 0.012), which resolved by 9 months postinjury. (b) TBI also caused
deficits in a working memory version of the task where the platform was moved to a novel location daily, but these never resolved (P = 0.004).

2009). During one variation of this procedure, a divider is
placed on one side of the maze during forced-exposure
trials, so that the animal is forced to enter that side and
reach a platform to escape from the water (sample stimulus). Immediately or after a delay, a free-choice trial is
given in which the divider is removed and the animal can
enter either side of the maze (comparison stimuli). When
the animal enters the same side of the maze as that
presented during the forced-exposure trial, the choice is
reinforced by escaping the water. Using this procedure,
Whiting and Hamm (2006) found that when the delay
between sample and comparison stimuli was relatively
short (i.e. 15 s), matching of sham animals and those
experiencing moderate lateral focal TBI reached ∼ 90%
accuracy. Although performance was disrupted at relatively long delays (e.g. 30 and 120 s) for both groups (80
and 75% respectively for sham), it was disrupted to a
larger degree following injury, with TBI animals displaying an ~ 15% reduction in accuracy relative to sham.
Similarly, performance was disrupted at 5 and 10 s delays
following unilateral parietal TBI in rats relative to sham
animals (Kline et al., 2002; Hoskison et al., 2009; Dash
et al., 2010; Kobori et al., 2011; Titus et al., 2016) and in
one study, deficits persisted until at least 16 weeks
postinjury (Hoskison et al., 2009; Dash et al., 2010; Kobori
et al., 2011; Titus et al., 2016).
Similar to results from DMTS and T-maze tasks, animal
studies suggest that WM, as measured by the eight-arm
radial maze, is impaired after mild to severe focal unilateral TBI (Lyeth et al., 1990; Enomoto et al., 2005;
Taylor et al., 2008; Sebastian et al., 2013; Shin et al., 2016).
The typical radial maze paradigm involves delayed
nonmatch to sample. Reinforcers are placed in four of the
eight arms, and animals must remember locations they
have already visited. Deficits, as measured by number of

errors (repeated visits), on this task after TBI may be
quite long lasting, as one study identified deficits even
when testing began 6 weeks after injury (Sebastian et al.,
2013).
Summary

Deficits in WM after TBI are robust in the preclinical
literature and relatively common in clinical practice across
many different approaches to testing. Most interesting is
the animal finding that WM deficits happen regardless of
location of injury. Given that WM is commonly considered to be frontal-dependent, this suggests that there
is more at work than mere tissue loss, and that other
factors, such as long-term alteration to neurotransmission,
may play a role. Whereas motivational deficits are
emphasized as a potential confound in clinical work, the
animal research appears quite reliable in this regard,
perhaps by using salient reinforcers such as escape from
water or palatable sucrose pellets.

Monoaminergic system changes following
traumatic brain injury
The brain regions that play prominent roles in executive
function tasks discussed above include the frontal cortex,
striatum (which includes the nucleus accumbens and
caudate-putamen), and hippocampus (Baron et al., 1985;
Hicks et al., 1993; McDonald et al., 2002; Chudasama and
Robbins, 2006). These regions, and the circuits they
form, are intimately dependent upon proper monoaminergic function. In the following sections, dopamine
(DA), serotonin (5-hydroxytryptamine, 5-HT), and norepinephrine (NE) changes following TBI are discussed,
with an emphasis on changes in brain regions known to
be critical for executive function. It should be noted that
although changes to monoaminergic systems are
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discussed in terms of disruptions, such changes may not
necessarily be detrimental but rather, may reflect compensatory adaptations.
Dopamine

DA is a prominent signaling system with widespread
effects and is critical for frontal-dependent, striataldependent, and hippocampal-dependent executive
function (Beaulieu and Gainetdinov, 2011; Haber, 2014;
Trantham-Davidson and Chandler, 2015). DA is heavily
concentrated in striatal regions, and serves a strong signaling function within the prefrontal cortex. Changes to
the DA system have been suggested to underlie chronic
behavioral and cognitive dysfunction following TBI
(Bales et al., 2009). This injury-induced disruption occurs
directly, but also by indirect glutamatergic and
GABAergic signaling alterations (Bales et al., 2009).
Clinical evidence

There are limited data available regarding the relationship between clinical TBI and DA transmission, and a
small portion of such data are equivocal. Using positron
emission and single-photon emission tomography, clinical imaging studies converge on moderate and severe
TBI-related reductions in striatal DA transporter densities when compared with healthy control participants
matched for age and educational status (Donnemiller
et al., 2000; Wagner et al., 2014). However, effects of
clinical TBI on DA receptor densities and metabolism
are less clear. Studies suggest that striatal D2 receptor
binding is altered following moderate or severe TBI,
although there are reports of both up-regulation and
down-regulation (Donnemiller et al., 2000; Wagner et al.,
2014). Similarly, it seems as though DA turnover is significantly altered following severe TBI (both increases
and decreases have been reported; Bareggi et al., 1975;
Porta et al., 1975; Vecht et al., 1976; Majchrzak et al., 1979;
Massucci et al., 2004). Such discrepant evidence may be
because of contributing sex differences and/or genetic
profiles (Wagner et al., 2007, 2014) in which DAergic
transmission is more heavily impacted for female patients
and for those with certain functional genetic variants
(Wagner et al., 2007).
Preclinical evidence

Given the sparse and sometimes conflicting evidence for
DA system changes following clinical TBI, as well as the
cross-sectional nature of the data that precludes the
detection of a causal relationship between TBI and
DAergic transmission, the field of experimental TBI has
focused on evaluating DA changes at each step in the
process of neurotransmission – synthesis, distribution,
and breakdown – using highly reproducible animal
models of injury.
Tyrosine hydroxylase (TH) is the rate-limiting enzyme
that is responsible for converting the amino acid

L-tyrosine

to L-DOPA. Given that L-DOPA is the
immediate precursor for DA synthesis, changes in TH
levels lead to alterations in DA signaling. Preclinical work
suggests that TH may be influenced differentially across
brain regions and time. Notably, disruptions in TH
activity may not be apparent during the acute post-TBI
phase (Huger and Patrick, 1979), but rather manifest
themselves later during recovery (Yan et al., 2001, 2007;
Shin and Dixon, 2011; Shin et al., 2011, 2012). Increased
TH in the frontal cortex and substantia nigra have been
observed following severe focal TBI in rats (Yan et al.,
2001, 2007), but only at chronic time points (28 + days
postinjury). In the same model of injury, Shin et al. (2011,
2012) determined the functional ability of TH to convert
L-tyrosine to L-DOPA, with a similar lack of differences
early postinjury, but decreases in TH function for TBI
rats at 1 and 4 weeks postinjury. While the effect of TBI
on TH activity has primarily been examined in the
striatum and substantia nigra of rats (Yan et al., 2001,
2007; Shin and Dixon, 2011; Shin et al., 2011, 2012),
mRNA levels for TH are elevated after mild blast injury
in the locus coeruleus and raphe nucleus (Kawa et al.,
2015), and protein levels and functional capacity of TH
are elevated after moderate focal injury in the prefrontal
cortex (Kobori et al., 2006). Together, the evidence suggests that TH function is disrupted following various
experimental TBIs, but the nature of disruption may be
dependent upon both the region of interest, and the time
point at which it is measured (i.e. increase or decrease in
activity). Vesicular storage of DA and other monoamines
may also be altered after TBI as some alleles of the
vesicular monoamine transporter are associated with
cognitive dysfunction after TBI in patients (Myrga et al.,
2016), and vesicular monoamine transporter is downregulated after experimental TBI, albeit only in female
rats (Xu et al., 2016).
Given that TH activity is disrupted post-TBI, it follows
that DA release and basal DA concentrations also
experience alterations. Indeed, evidence from highperformance liquid chromatography and western blot
studies with rats suggests that there are initial increases in
DA levels in the frontal cortex and striatum postmild
blast or postsevere focal TBI that persists for at least
28 days (Massucci et al., 2004; Kobori et al., 2006; Kawa
et al., 2015). While higher DA levels have been measured
post-mortem after TBI, in-vivo recordings of DA release
from presynaptic neurons using fast scan cyclic voltammetry or microdialysis show significantly lower levels for
severe and moderate focal-TBI rats up until 8 weeks
postinjury when compared with sham rats (McIntosh
et al., 1994; Wagner et al., 2005; Shin and Dixon, 2011;
Huang et al., 2014a; Chen et al., 2015, 2017). In turn, DA
transporter down-regulation may be due to the significant, chronic reduction in frontal and striatal DA
release following TBI, leading to a reduction in DA
reuptake and clearance from the synapse (Yan et al., 2002;
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Wagner et al., 2005; Wilson et al., 2005; Huang et al.,
2014a; Shimada et al., 2014). The effect of TBI on DA
transporter down-regulation is true not only for the
frontal cortex and striatum (Yan et al., 2002; Wagner et al.,
2005; Wilson et al., 2005), but also for the midbrain
(Shimada et al., 2014), and occurs even in the case of mild
TBI (Yan et al., 2002; Wagner et al., 2005; Wilson et al.,
2005; Huang et al., 2014a; Shimada et al., 2014). This is
perhaps because of the action of DA as an excitotoxic
agent, in which elevated levels in the acute post-TBI
phase may lead to excitotoxicity and oxidative damage,
resulting in lower levels of DA release at chronic time
points and compensatory changes in DA transporter
densities (Olney et al., 1990; Wagner et al., 2005).
Moreover, DA transporter down-regulation appears to be
a chronic effect and persists for at least 28 days postinjury
for rats (), although additional time points have not be
evaluated.
In rat models, some have reported transient (< 24 h)
reductions in D1 receptor density in the striatum after
TBI (Henry et al., 1997), but another study observed a
complex relationship at 24 days postinjury of decreased
D1 receptor density in dorsal striatum, and increased D1
levels in the nucleus accumbens, but only after mild TBI
(Vonder Haar et al., 2016). Moreover, no changes in
striatal D2 receptor densities have been recorded across
multiple time points (Henry et al., 1997; Wagner et al.,
2005, 2008; Vonder Haar et al., 2018).
In addition to reuptake by transporters, the second
mechanism by which DA is removed from the synapse is
by enzymatic degradation; the enzymes catechol-Omethyl transferase (COMT) and monoamine oxidase
(MAO) break down DA into its primary metabolites,
3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid. Although there have been no studies
assessing effects of TBI on COMT or MAO directly,
existing evidence suggests that DA metabolism may be
affected acutely post-TBI. However, there is some discrepancy in the preclinical TBI field, in which some work
suggests that there are heightened levels of DOPAC and
homovanillic acid of rats in the short term, corresponding
with elevated DA levels (Massucci et al., 2004; Shin and
Dixon, 2011; Shin et al., 2012), while others report
reduced levels of such metabolites in mice and rabbits
during acute recovery (Edvinsson et al., 2009; Shen et al.,
2011). In addition, DOPAC/DA ratios (a measure of DA
turnover) are significantly altered in rats postinjury (both
increases and decreases have been reported; Massucci
et al., 2004; Shen et al., 2011), giving evidence for altered
DA metabolism and not simply an up-regulation or
down-regulation of DOPAC as a response to changes in
DA levels. However, by 7 days postinjury, no differences
were found between sham and injured rats, suggesting
that DOPAC levels (and potentially COMT and/or MAO
levels) become normative during the postacute recovery
period (Shin and Dixon, 2011; Shin et al., 2012).

Summary

In addition to chronic, detrimental effects of TBI on DA
synthesis, distribution, and breakdown, moderate focal
TBI results in a significant, progressive loss of DA neurons
in the substantia nigra (Wagner et al., 2009; Hutson et al.,
2011; van Bregt et al., 2012), which may be representative
of the established link between TBI and the development
of Parkinson’s disease (Semchuk et al., 1993). Thus, TBI
has widespread effects on the DAergic system, affecting all
aspects of DA neurotransmission. Given the evidence from
both experimental and clinical TBI fields, treatment has
focused largely on providing DAergic pharmacotherapies
(e.g. D-amphetamine, methylphenidate) for TBI patients
to aid in symptom reduction following injury by increasing
DA signaling (Bales et al., 2009), although these pharmacotherapies are not without potential pitfalls (see below:
Special Considerations for Pharmacotherapy following
TBI). Moreover, given the unique time course of changes
to DA after TBI, the exact timing of pharmacotherapies
will be of critical importance.
Norepinephrine

Of all the monoaminergic systems, NE has received the
least attention in regard to alterations following TBI. DA
is converted to NE by the rate-limiting enzyme, DA-βhydroxylase. Therefore, the disruptions in TH or DA
activity discussed above also contribute to alterations in
NE activity.
Clinical evidence

The two clinical TBI studies that evaluated changes in
NE signaling relative to non-TBI control participants
suggest that brain injury increases NE metabolism,
indicated by heightened levels of NE’s primary metabolite, 3-methoxy-4-hydroxyphenylglycol. However, this
was only measured at between one and 12 days postinjury (Markianos et al., 1992, 1996). Although NE has
not been a prime target of interest for clinical TBI
research, selective NE reuptake inhibitors are a relatively
common treatment for depression and anxiety, and may
also improve attention, all of which suffer some impairment in TBI patients (Hibbard et al., 1998; Jorge and
Robinson, 2003; Juengst et al., 2017). Thus, further
clinical work investigating NE activity following clinical
TBI is needed.
Preclinical evidence

Experimental work suggests that brain injury leads to
significant increases in NE levels in the prefrontal cortex,
hippocampus, cerebellum, and hypothalamus of rats (at
2 h, 7 days, and 14 days), which corresponds with
increased TH levels at these same time points (Huger
and Patrick, 1979; Kobori et al., 2006; Kawa et al., 2015).
In addition, acute increases in NE occur specifically at
the site of injury, followed by a return to levels comparable to those of sham rats by as early as one week postinjury (McIntosh et al., 1994; Levin et al., 1995;
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Dunn-Meynell et al., 1998; Fujinaka et al., 2003). Thus,
the evidence suggests that relatively acute disruptions
occur during NE synthesis and distribution/release following injury in experimental studies, although clinical
work is needed to validate these findings in TBI patients.
In addition to significant increases in basal NE, early
studies suggested that α1A receptor subtypes are transiently reduced at the injury site and may persist until
30 days postinjury in rats (Prasad et al., 1992; Levin et al.,
1995), while more current work reports increased α1A
receptor mRNA in the medial prefrontal cortex following
TBI (Kobori et al., 2011).
Summary

While NE transmission is likely disrupted following TBI,
research is lacking in specificity of the nature of those
disruptions. It is likely that NE signaling disruption following TBI could influence executive function through
the locus coeruleus innervation of the prefrontal cortex
(Logue and Gould, 2014). In particular, whether densities of other receptor subtypes are altered, what changes
occur at the NE transporter, and the degree to which
these changes may contribute to behavioral dysfunction
remain open questions. It may also be a clinical concern
that elevated NE levels have been detected after TBI,
yet selective NE reuptake inhibitors may be used clinically for a host of conditions in these patients. Overall,
research regarding TBI and NE disruption is lacking and
there is a critical need for both clinical and
preclinical work.
Serotonin

Although more research has been conducted on 5-HT
compared with NE, relatively little work has investigated
the mechanisms by which TBI disrupts 5-HT signaling.
Clinical evidence

Clinical studies suggest that 5-HT transmission is indeed
disrupted following TBI, revealed by significant changes
in 5-HT metabolites in the cerebrospinal fluid of TBI
patients (both increases and decreases have been reported; Porta et al., 1975; Vecht et al., 1976; Majchrzak et al.,
1979; Markianos et al., 1992, 1996). Discrepancies in the
nature of such changes in 5-HT metabolite levels may be
explained, at least in part, by measurement time points,
with 5-HT being elevated during the acute post-TBI
phase and reduced during chronic recovery (Porta et al.,
1975; Vecht et al., 1976; Majchrzak et al., 1979; Markianos
et al., 1992, 1996). The mood-altering effects of 5-HT
have been a primary area of focus, given that the development of mood disorders such as depression and anxiety
are prevalent following brain injury (Hibbard et al., 1998;
Jorge and Robinson, 2003; Juengst et al., 2017) and the
most common treatment for such disorders are selective
5-HT reuptake inhibitors (SSRIs; Ciuna et al., 2004).
Although effects have not been assessed directly, it is
possible that 5-HT signaling disruption following TBI

may also influence executive function (Cifariello et al.,
2008). Indeed, some have reported significant inverse
correlations between 5-HT signaling and impulsive
behavior (Harrison et al., 1997; Dalley et al., 2002), and
inverse relations have been identified between 5-HT
metabolites and aggression levels, although these may
also be mediated by DA signaling (Coccaro et al., 2010).
Preclinical evidence

Tryptophan hydroxylase (TPH) is the rate-limiting
enzyme that is responsible for interacting with the
amino acid tryptophan and converting it to 5-HT, which
is then acted upon by DOPA decarboxylase to create
5-HT. Although TPH is significantly increased in the
dorsal raphe nucleus and locus coeruleus in rats acutely
following mild blast TBI (i.e. up until 24 h), by 48 h postTBI, TPH levels return to those that are comparable to
sham rats (Kawa et al., 2015). Similarly, acute changes
have been observed in rat basal 5-HT levels post-TBI
(10 min; Busto et al., 1997), suggesting that acute disruptions in TPH production directly affect 5-HT levels.
However, there is some discrepancy as to whether 5-HT
levels return to normal early during recovery. Some have
reported a return to sham levels by seven days postinjury
(Kawa et al., 2015), while others suggest that 5-HT levels
are elevated until at least 2 weeks postinjury (Mustafa
et al., 2017). Such discrepant findings may be because of
the use of different injury models across studies, in which
mild TBI induced by weight drop may affect 5-HT
transmission longer into the recovery period than that
induced by blast (Kawa et al., 2015; Mustafa et al., 2017).
Given the limited and sometimes conflicting evidence,
further preclinical work is needed to dissociate the
mechanisms by which TBI affects 5-HT levels.
In addition to relative acute and transient disruptions in
5-HT synthesis and basal concentrations post-TBI, there
are no changes in 5-HT2A receptor densities in the
motor, prelimbic, agranular, sensory, or cingulate cortices
of rats at 15 days postinjury (Dam et al., 2013), although
more acute time points have not been assessed. In contrast, significant increases in 5-HT1A densities in the
hippocampus have been shown at 15 days postinjury
(Wilson and Hamm, 2002), which may contribute to
memory deficits that are seen following TBI (Dale et al.,
2016). Changes in other 5-HT receptors have not been
evaluated after TBI, potentially because of a lack of
strong radioligands for human patients, or because of the
inherent complexities in studying the numerous receptors and their actions.
In terms of 5-HT deactivation, moderate or severe TBI
produces significant, chronic reductions in 5-HT transporter densities in the frontal and cingulate cortices of
rats (Abe et al., 2016). At the same time, moderate TBI
leads to chronic increases in 5-HT transporter densities in
the raphe nucleus while having no effect on densities in
the hippocampus, thalamus, or amygdala of rats (Dam
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et al., 2007). Together, the evidence suggests that 5-HT
reuptake is dysregulated following TBI, but the nature of
such disruption may depend upon injury type and brain
region. In addition to 5-HT deactivation by reuptake,
5-HT enzymatic degradation may be disrupted following
TBI, which is in line with clinical evidence. Indeed,
significant reductions in 5-HIAA in the rat hippocampus
have been observed at 30 min post-TBI (Eschun et al.,
1992), although additional time points have not been
assessed.
Summary

Given the significant reduction in 5-HT transporters in
the frontal cortex, a critical region for executive function
(McDonald et al., 2002; Chudasama and Robbins, 2006),
as well as disruptions in 5-HT metabolism, it is possible
that disruptions in 5-HT breakdown and removal from
the synapse contribute to behavioral impairments after
TBI, although effects have not been assessed directly. In
addition to replicating the results discussed above using
alternative models of experimental TBI, the efficacy of
commonly prescribed SSRIs (i.e. 5-HT transporter
antagonists) on executive function following TBI should
be assessed thoroughly given that a large portion of TBI
patients experience postinjury depression and/or anxiety
(Hibbard et al., 1998; Jorge and Robinson, 2003; Juengst
et al., 2017) and are likely to be prescribed such
pharmacotherapies.

Special considerations for pharmacotherapy
following traumatic brain injury
Reduced sensitivity to reinforcement

TBI patients show significant impairments in executive
function, which may be due, in part, to insensitivity to
contingencies and natural reinforcement processes.
Executive function tasks include reinforcing (and often
concurrent punishing) consequences for appropriate
responding, with optimal responding in these tasks producing higher rates of reinforcement. However, individuals with TBIs show reduced sensitivity to and
awareness of reinforcement contingencies (Schlund and
Pace, 2000; Schlund et al., 2001; Schlund, 2002a, 2002b;
Larson et al., 2007), and are slower to adapt choices following changes in reinforcing contingencies compared to
non-TBI controls (Schlund et al., 2001; Schlund, 2002a,
2002b). All of these processes are directly dependent on
DAergic signaling, and a large literature has demonstrated the role of DA in primary reinforcement
(Cameron et al., 2014; Shnitko and Robinson, 2015),
reward expectation (Schultz et al., 1997; Cocker et al.,
2016), and punishment salience (Tomer et al., 2014; van
der Schaaf et al., 2014; Jean-Richard-Dit-Bressel et al.,
2018). Despite these large effects in patients, sensitivity
to contingencies may not be impacted at the most basic
level. As such, one study examined responding under
basic schedules of reinforcement (e.g. fixed ratio, fixed
interval, variable ratio, variable interval) between sham

and rats undergoing experimental TBI and found no
notable deficits in TBI rats (Vonder Haar et al., 2016).
However, in the same model of TBI, rats displayed
substantial deficits in simple discriminations (Martens
et al., 2012; Vonder Haar et al., 2014a, 2014b) and aberrant
(but not purely disadvantageous) choice behavior on the
RGT (Shaver TK, Ozga JE, Zhu B, Anderson KG,
Martens KM, Vonder Haar C, unpublished data), suggesting that discrimination between concurrently available contingencies may be reduced, which may drive
executive function deficits in TBI patients. Given the
scope of this problem, augmented behavioral therapies
may need to be developed specific to patients with brain
injury in order to appropriately serve this population
(Knight et al., 2002; Wood and Alderman, 2011). These
foundational problems should also be considered when
assessing executive function in animal models of TBI.
Altered pharmacology after traumatic brain injury

While pharmacotherapies to treat TBI remain a primary
interest of the medical community, several concerns have
been raised about factors that may alter the efficacy of
these treatments. We have opted to focus primarily on
mechanisms of monoaminergic dysfunction because of
their suspected role in executive impairment; however, it
should be noted that effects of TBI extend far beyond
the monoamines. Notably, altered pharmacokinetics
have been observed by multiple mechanisms after TBI
and for many different drugs. In particular, hepatic
cytochrome-P450 enzymes are upregulated, and proteindepot binding in blood may be reduced, resulting in
faster metabolism of many substances (Empey et al.,
2006; Anderson et al., 2015). Parsing these metabolic
changes is further compounded by disruption of the
blood–brain barrier (Stowe et al., 2000; Hay et al., 2015;
Prakash and Carmichael, 2015), potentially resulting in
higher than normal drug concentrations, and/or other
interfering proteins reaching neural tissue as blood–brain
barrier permeability shifts after injury. Together, these
factors present challenges to both the experimental
researcher and the clinician regarding concentration and
frequency of dosing, and may help explain the numerous
treatment failures experienced in the field of TBI.
While alterations to pharmacokinetics are concerning, fully
understanding the changes in pharmacodynamics after
TBI are an even more difficult challenge. Monoaminergic
metabolism, as well as receptor and transporter densities
are all altered at some point following TBI, leading to the
question of whether drugs exert the same effects in TBI as
non-TBI populations (McAllister et al., 2011a), or whether
TBI patients represent a unique subgroup with regard to
conventional pharmacotherapies. In addition, alterations in
monoaminergic signaling are varied during acute versus
chronic recovery, and thus, how pharmacotherapies affect
executive function at different time points is also important
for a full understanding of pharmacotherapy following TBI.

TBI and executive function Ozga et al. 629

Dopaminergic therapies

DA pharmacotherapies, such as amantadine hydrochloride, bromocriptine, D-amphetamine, and methylphenidate (DA agonists), are reported to have cognitiveenhancing (i.e. attention and working memory) effects in
TBI patients during chronic recovery (see Bales et al.,
2009; Liepert, 2016 for reviews). Therefore, these and
other pharmacotherapies (apiprazole, L-deprenyl, and
methamphetamine) aimed at increasing DA signaling
have been tested following experimental TBI. Several of
these drugs show promise in reducing chronic signaling
deficits following injury, such as increasing DA levels in
the striatum and substantia nigra while also reducing
neuronal death (Zhu et al., 2000; Wagner et al., 2008,
2009; Rau et al., 2012; Huang et al., 2014a, 2014b; Wang
et al., 2014; Tan et al., 2015; Phelps et al., 2017). In turn,
performance is improved acutely for TBI animals on
traditional tasks for assessing cognitive deficits, such as
the MWM and novel-object recognition tasks, following
administration of such therapeutic agents (Zhu et al.,
2000; Wagner et al., 2008, 2009; Rau et al., 2012; Huang
et al., 2014a, 2014b; Wang et al., 2014; Tan et al., 2015;
Leary et al., 2017; Phelps et al., 2017). At the same time,
pharmacotherapies that reduce DA signaling, such as
haloperidol and resperidone, exacerbate acute MWM
deficits, in both TBI and non-TBI animals (Wilson and
Hamm, 2002; Kline et al., 2007, 2008; Hoffman et al.,
2008), giving support for a significant contribution of
reduced DA signaling in cognitive dysfunction.
Most recently, work has focused on investigating how
DA therapies may affect higher-order executive function
using tasks such as those discussed earlier in this review.
Similar to memory-related assessments, drugs that
increase DA signaling (amantadine and D-amphetamine)
reduce chronic deficits in motor impulsivity in TBI animals on the 5CSRTT (Vonder Haar et al., 2016), although
effects of amantadine were accompanied by potential
psychomotor slowing or motivational issues across groups.
Perhaps most interesting was the fact that D-amphetamine selectively reduced impulsivity, but only in
severely-injured rats; an effect that we have observed
again recently (Fig. 2). This provides strong evidence
that those with TBI may not respond to pharmacologic
treatments in the same manner as those without such
injury.
Indeed, human studies using functional MRI give evidence for less activation in various brain regions for TBI
patients following acute dosing of bromocriptine when
compared with healthy control participants (McAllister
et al., 2011a). Thus, TBI patients may not respond in the
same way as non-TBI patients to pharmacotherapy, both
neurochemically or behaviorally. In addition, DA agonistic therapies may not have the same effect on all types
of executive function, as evidenced by methylphenidate
aiding in chronic recovery of working memory function in
TBI patients (Liepert, 2016). These factors may become

even more confounding when considering that mixed in
with positive findings are studies claiming efficacy
without achieving statistical significance (Kim et al.,
2006), evidence for similar rates of recovery under placebo or nondrug conditions (Pavlovskaya et al., 2007), and
differential drug effects between TBI and non-TBI animals (Vonder Haar et al., 2016; Shaver TK, Ozga JE, Zhu
B, Anderson KG, Martens KM, Vonder Haar C, unpublished data), ), null drug effects (Wilson and Hamm,
2002; Ripley et al., 2014), as well as the need to consider
natural aging- or sex-related changes in monoamine
metabolism and drug responsiveness. When combined
with studies that have identified altered DA pharmacology in TBI patients, it is clear that additional research is
needed using animal models to determine whether current DAergics may be effective in treating complex
cognitive dysfunction such as decision-making.
Noradrenergic therapies

Although NE signaling deficits have been observed
following TBI, evaluations of cognitive performance
following administration of pharmacotherapies targeting
the NE system are relatively sparse and conflicting. Some
have suggested that too much NE signaling is a cause for
concern in the acute recovery phase of TBI patients, with
α1 receptor antagonists (e.g. prazosin) improving MWM
performance in rats with experimental TBI at 14 days
postinjury (Kobori et al., 2011). However, others have
suggested that too little NE may be the issue. In clinical
assessments, guanfacine, an a2A receptor agonist,
improved working memory deficits following mild TBI at
one month postinjury (McAllister et al., 2011b), although
preclinical assessments have reported no effect of guanfacine on MWM performance at 14 days postinjury
(Kobori et al., 2011). There is also mixed evidence
following administration of atomoxetine, a NE reuptake
inhibitor, in which clinical assessments suggest no effect
on attentional deficits at one year or more postinjury
(Ripley et al., 2014), while preclinical work suggests
improved working memory and response inhibition following atomoxetine treatment during both, acute and
chronic recovery of TBI animals (i.e. 14 days and
12 weeks; Reid and Hamm, 2008; Vonder Haar et al.,
2016). In addition to the sparse, and sometimes conflicting, evidence, atomoxetine has a low binding affinity
for the DA transporter (Bymaster et al., 2002); thus, its
effects on executive function may not be due to its action
on NE per se but rather by its effects on DA.
Serotonergic therapies

The majority of work with 5-HT agents has focused on
improving disruptions in mood, such as depression and
anxiety. However, executive function deficits are prevalent in patients with depressive disorders (Alves et al.,
2014), and 5-HT agents may simultaneously improve
executive function and mood (Gualtieri et al., 2006). Few
studies have investigated how 5-HT pharmacotherapies
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Fig. 2

Differential effects of amphetamine challenge on motor impulsivity after traumatic brain injury (TBI). (a) High-dose amphetamine significantly reduced
impulsivity on the five-choice serial reaction time task, but only for animals with a severe focal TBI (P = 0.002) (adapted with permission from Vonder
Haar et al., 2016, copyright 2016 American Chemical Society). (b); High-dose amphetamine significantly reduced impulsivity on the rodent gambling
task in animals with a severe focal TBI (P = 0.011) (Ozga JE, O' Hearn CM, Shaver TK, Lake AD, Vonder Haar C, unpublished data). Adaptations are
themselves works protected by copyright. So in order to publish this adaptation, authorization must be obtained both from the owner of the copyright
in the original work and from the owner of copyright in the translation or adaptation.

may impact cognitive function directly either following
clinical or experimental TBI. Similar to DA agonists,
various 5-HT agonists (N-n-propyl-3-ethoxyquinoxaline2-carboxamide, 8-OH-DPAT, repinotan, buspirone, and
fluoxetine) produce increases in basal 5-HT levels as well
as reduced neuronal cell loss and contusion volume following experimental TBI, corresponding with a reduction in acute and chronic anxiety-like (elevated plus
maze, marble burying, and open field) and depressivelike (sucrose preference) behaviors (Kline et al., 2001,
2012; Cheng et al., 2007, 2008; Olsen et al., 2012; Monaco
et al., 2014; Bhatt et al., 2017).
In addition to emotion-related behaviors, a variety of
5-HT1A receptor agonists improve acute and chronic
MWM performance in TBI animals, suggesting that
deficits in 5-HT signaling post-TBI contribute to cognitive deficits (Kline et al., 2001, 2012; Cheng et al., 2007,
2008; Olsen et al., 2012; Monaco et al., 2014; Bhatt et al.,
2017). However, others have reported no effect on acute
MWM performance in TBI animals following systemic
fluoxetine administration, an SSRI that is prescribed
commonly for depression and anxiety (Wilson and
Hamm, 2002). Given the limited evidence for how 5-HTenhancing drugs may affect cognitive function, in conjunction with a lack of work using higher-order executive
function tasks, further work is needed to evaluate
how common 5-HT pharmacotherapies (SSRIs, in particular) affect working memory, decision-making, and
impulsivity.

Efficacy of pharmacotherapies

Reports showing mixed efficacy of pharmacotherapies in
TBI populations (both human and nonhuman animal) are
likely due to several factors, including timing of treatment during recovery. As an example, NE antagonists
have shown promise in reducing hippocampally dependent cognitive deficits, while agonists have been shown
to produce no improvements during acute recovery
(Kobori et al., 2011). In contrast, during chronic recovery,
NE agonists reduce cognitive function deficits
(McAllister et al., 2011b; Vonder Haar et al., 2016),
although the magnitude of effect is small. In addition to
the timing of drug administration, alterations in monoaminergic pharmacodynamics may lead to differences in
dosing guidelines needed to produce significant effects
on executive function for TBI populations. Indeed, some
have suggested that increased doses of DAergic therapies
are needed to affect executive function following TBI in
rats (Bondi et al., 2014; Vonder Haar et al., 2016; Leary
et al., 2017; Shaver TK, Ozga JE, Zhu B, Anderson KG,
Martens KM, Vonder Haar C, unpublished data), which
is reflective of altered pharmacokinetics or pharmacodynamics following injury. Thus, the efficacy of traditional
pharmacotherapies for reducing executive function deficits likely depends upon when during recovery and in
what doses drugs are administered. Together, changes in
pharmacodynamics and pharmacokinetics following TBI
pose challenges to clinicians and researchers, and may
explain the high frequency of treatment failures that exist
in the field.
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Deficits in executive function and monoaminergic signaling may also help to explain the heightened prevalence of alcohol, cocaine, opioid, marijuana, and
amphetamine use disorders in TBI populations compared with those without such injuries (Walker et al.,
2003; O’Phelan et al., 2008; Golub and Bennett, 2013;
Singh et al., 2014; Ma et al., 2015; Ramesh et al., 2015).
Given the large-scale alterations to monoaminergic systems following TBI, increased drug-seeking behaviors,
particularly of psychostimulants, may represent an effort
to ‘self-medicate’. While this simple pharmacological
argument is attractive, it is unlikely to account for the
entirety of substance abuse after TBI. In particular,
research has showed that impulsivity is intimately linked
to the development of substance abuse (Perry et al., 2005;
Dalley et al., 2007), and thus may be a mediating factor.
Further, deficits in behavioral flexibility are likely to
promote continued drug dependence, even in the face of
detrimental outcomes (Istin et al., 2017). Given that TBI
patients demonstrate deficits in all of these domains,
these are likely contributors to initiation, exacerbation,
and maintenance of substance abuse following injury.
However, data on increased incidence after TBI are a
classic case of correlation (i.e. does substance abuse cause
TBI or does TBI cause substance abuse?), with a lack of
concrete prospective studies in humans. Importantly, a
number of brain injuries occur while under the influence
of various substances, particularly alcohol, with some
studies ranging as high as 47% (Andelic et al., 2010).
Despite this figure, some studies report no relationship
between previous substance abuse and brain trauma
(Lange et al., 2014) while others identify relationships
only within injury subgroups (Andelic et al., 2010), and
indeed, alcohol intoxication at the time of injury is
associated with reduced injury severity in humans and
animals (Andelic et al., 2010; Goodman et al., 2013;
Kanbak et al., 2013; Raj et al., 2015).
The argument for TBI as causal to addiction is much
stronger when considering the animal evidence. To date,
few studies have examined voluntary drug selfadministration after TBI. However, these studies largely converge on the conclusion that animals with injury
self-administer more drug, or escalate their intake more
quickly, across both alcohol and cocaine (Lim et al., 2015;
Mayeux et al., 2015; Weil et al., 2016; Vonder Haar et al.,
2018), although such self-administration may depend
upon injury type, severity, and substance, as one group
found no changes in cocaine intake after blast injury
(Muelbl et al., 2018), while others have seen increased
alcohol intake after blast (Lim et al., 2015), and increased
cocaine after mild or severe focal injury (Vonder Haar
et al., 2018). Moreover, studies have found interesting
subgroup differences within TBI animals with regard to
acquisition of drug self-administration (Lim et al., 2015;
Vonder Haar et al., 2018), in which some TBI rats show
faster acquisition of drug self-administration than others,

suggesting potential biological or behavioral mediators of
resilience that warrant investigation. In particular, both
DA-related markers (e.g. DA-regulated and cAMPregulated neuronal phosphoprotein) and multiple
inflammatory markers (e.g. cytokines, glial activation)
have been affiliated with increased intake (Vonder Haar
et al., 2018) or greater sensitivity or preference for drugs
of abuse (Lowing et al., 2014; Merkel et al., 2017a, 2017b).
As research moves forward, a potential propensity to
substance abuse should be a prime consideration when
evaluating therapeutics, especially when considering
implementation in clinical populations.

Conclusion

In this review, we have identified major changes in
executive function following TBI, namely impulsivity,
behavioral flexibility, and working memory (Fig. 3).
These deficits are present in both human patients, and in
animal models of brain injury. While the clinical effects
are well-established, the animal literature lags behind.
Much of the focus of the experimental TBI field has
been on relatively simple assessments of learning and
memory, such as the MWM, to the neglect of more
complex cognitive function. Further studies are needed
to characterize executive function deficits across the
many existing injury models in order to generate a more
clinically-relevant behavioral phenotype which may then
be used to effectively screen treatment options.
Moreover, these deficits in executive function may be
driven by the major alterations in monoaminergic neurotransmission such as dopamine, norepinephrine, and
serotonin (Fig. 3). However, the field is limited in its
consensus on the exact nature of these changes, and
there appear to be important factors related to injury type
and severity, as well as time from injury. More research is
needed at both the clinical and preclinical level to resolve
major conflicts (e.g. up-regulation and down-regulation of
DA receptors; increased NE despite cognitive impairments that may be alleviated by NE agonists) so that we
may better understand the time course of these changes
and target therapeutics appropriately.
Finally, these changes in both executive function and
monoaminergic status may in turn complicate developing, administering, and achieving efficacious results not
only with novel compounds, but also with traditional
treatments for psychiatric-like symptoms experienced by
these individuals. In particular, reduced sensitivity to
contingencies surrounding the individual may limit the
efficacy of pharmacotherapies or require an integrated
approach with cognitive-behavioral therapies. In addition, altered doses, or less conventional drugs may be
required to treat behavioral symptoms, accounting for
monoaminergic alterations. Finally, the abuse potential
for drugs, particularly psychostimulants which may
remediate impulse control issues, needs to be carefully
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Fig. 3

Schematic representation of dysfunction after traumatic brain injury (TBI). Monoamine disruptions are common starting mere hours after injury, with
some continuing for months or longer. Monoamines influence various types of executive function, and this dysregulation after TBI may account for
some of the common behavioral disturbances that are observed. Finally, both altered monoamines and functional impairments may converge to explain
several post-TBI complications, including numerous therapeutic failures, and increased propensity for substance abuse and dependence. Notably, the
intertwined nature of altered functional and structural changes make it difficult to fully parse the separate factors that challenge clinical treatment of
TBI. DA, dopamine; 5-HT, 5-hydroxytryptamine; NE, norepinephrine.

considered given links between substance abuse and
TBI populations.
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